Precision Medicine

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

A market poised for 31% annual growth signals a new era for Alcohol-associated Liver Disease. As pharma chases a cure, a new class of drugs emerges.

A new partnership between Biocartis and City of Hope seeks to transform pancreatic cancer outcomes by pairing breakthrough biomarkers with rapid diagnostic technology.

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

Millions suffer from Dry Eye Disease with few good options. A new clinical trial is now testing a drug tailored to a patient's DNA. Is this the end of trial-and-error?

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

A Stanford spinout just revealed a wearable that measures the body's master stress hormone in real time. This isn't just a new gadget; it's a fundamental shift.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.

With 80% of trials delayed, the life sciences industry is gathering to tackle its patient enrollment crisis. Can new partnerships and AI finally move the needle?

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.